CClinicalTrials.gg
CompletedNCT04520633TRAQUEUpdated Dec 15, 2023

Validity of a French Version of the Severe Asthma Questionnaire

An observational study in Asthma, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-12-15.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
188
Ages
18 Years to 99 Years
Sex
All
01

Study summary

"Severe asthma affects only 5% of asthmatics, but has a considerable impact on patients owing to the respiratory disability linked to asthma but also complications from oral corticosteroid (OCS) therapy.

Biologics have recently been made available, and improve quality of life (QoL)severe asthma patients. Having a reproducible and reliable measuring tool of QoL for severe asthmatics would be useful for assessing the impact of the various interventions proposed.

QoL questionnaires currently used in respiratory diseases are not specific to severe asthma. They are very focused on respiratory disability, but for example do not take into account the impact of treatments, especially oral steroids.

The Severe Asthma Questionnaire (SAQ) is the very first tool specifically designed to assess the health related quality of life of severe asthma population. The development of its use goes through the validation of this questionnaire in its French translation available since September 2019. "

Read the detailed description

"Difficult to treat asthma affects about 17% of the asthma population, among which 5% have severe asthma.

For these patients, the disease is often a burden to their professional, family and personal life, significantly altering their quality of life.

Current recommendations on medical management aim at asthma control and reduction of exacerbations. While there are now biologics that effectively address these objectives, they are still struggling to demonstrate their effectiveness in term of quality of life improvement.

Although in real life, patients well responding to biologics often report ""a changing life"", this is not well demonstrated in clinical trials, which only bring out modest variations in quality of life (mainly AQLQ) and asthma control scores. This may be due to the fact that currently used scores, measure either the quality of life in a generic way, or asthma control (dyspnea, use of rescue treatments) rather than asthma specific quality of life, and do not take into account the burden of oral steroids.

For this specific population of asthmatics, even the dedicated scores (11 scales in the adult population and 6 in the pediatric population) have trouble measuring variations in quality of life. They hardly ever manage to demonstrate a difference in quality of life between mild asthma and severe asthma.

However, just like oral steroids sparing, improving quality of life is of concern for physicians.

The development of Patient Reported Outcome (PRO) instruments follows rigorous scientific methodology. The Severe Asthma Questionnaire (SAQ) is a specific instrument for measuring quality of life in severe asthma. It was developed and validated in English by the University of Plymouth in 2018, according to the current recommendations, in an attempt to respond to the lack of specificity of the former quality of life tests.

It has gone through forward and backward translation process into French thanks to the Mappy Trust organization. It seems important to validate, in its French translation, the psychometric properties of the SAQ questionnaire, a specific instrument measuring quality of life for severe asthmatics.

Practical considerations:

  • Useful data cf primary and secondary objectives will be collected at the first and the 6th month.
  • Standard Operating Procedures: Patient recruitment will only take place in Bichat Hospital. Questionnaires and forms will be lend to the severe asthmatics coming to consultation and day hospital thanks to clinical research associate. Data will be anonymized and collected by a clinical research associate (fulfilled forms and questionnaire and medical file). Data management, data analysis will be ensured by Clinical Research Unit of Bichat Hospital.
  • Sample size assessment : estimated on FALISSARD assumption: 320 patients.
  • Plan for missing data: usual way for each quality of life questionnaire, enlarged 6th month visit period to collect 6th month reevaluation.
  • Statistical analysis plan: cf section primary and secondary objectives.
  • Quality assurance plan: Data validation and registry procedures, including any plans for site monitoring and auditing will be ensured by the Clinical Research Unit of Bichat Hospital.
  • Data checks: Predefined rules for range will be pre-configure in the eCase Report Form (CRF) computed in REDCap. The data dictionary that contains detailed descriptions of each variable used by the registry (cf inclusion/exclusion criteria, primary and secondary outcome), including the source of the variable, and normal ranges is described in a specific document based on which the eCRF will be built. "
02

Conditions studied

  • Asthma

Browse trials for

Keywords

  • severe asthma
  • quality of life questionnaire
03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 188 is above the median of 150 across 970 observational studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with severe asthma

Inclusion criteria

  • Adult patients
  • Patients diagnosed with severe asthma as defined by the international consensus statement from European Respiratory Society and American Thoracic Society 2014: Asthma which requires treatment for GINA steps 4-5 asthma (high dose Inhaled Cortico Steroids > 1000 micrograms and Long Action Beta Agonist or leukotriene or theophyllin modifier ) for the previous year

    *or systemic CorticoSteroids for 50% of the previous year to prevent it from becoming ''uncontrolled'' or which remains ''uncontrolled'' despite this therapy

  • Patient informed and not opposed to participating

Exclusion criteria

Exclusion criteria :

  • Lung cancer, heart failure or Chronic Obstructive Pulmonary Disease, or other respiratory disease that may affect the evaluation of asthma
  • Patient unable to read French
  • Patient unwilling to take part in the research
  • Patient under guardianship / curators
  • Patient under AME
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
188 participants (actual)
Patient registry
No

Groups and cohorts

  • control level stable

    severe asthma for which the control level is stable (variation in ACT score \<3 between M0 and M6) contributing to the test-retest

  • biologic initiation

    introduction or modification of biotherapy at M0

    Other: biologic initiation

Interventions

  • Otherbiologic initiation

    introduction or modification of biotherapy at M0

06

What researchers measure

Primary outcomes

  1. Factorial validity of french traduction of SAQ (Severe Asthma Questionnaire )

    Factorial validity (evidence that the instrument measures a single concept): principal component analysis of all items

    Time frame: 1 month

  2. Internal consistency of french traduction of SAQ

    Internal consistency (intercorrelation of items that contribute to a score): Item total correlation and Cronbach's alpha coefficient

    Time frame: 1 month

  3. Construct validity of french traduction of SAQ

    Construct validity (strength of correlation testing a priori hypotheses (discriminant and convergent validity) and degree to which the PRO instrument can distinguish among groups hypothesized a priori to be different (known groups validity)): Spearman correlation between SAQ and ACT\*, ACQ\*, miniAQLQ\*, SGRQ\*, SF36\*, EQ 5D 5L\*, EQ 5D VAS\*, OCS dose, Forced expiratory volume in 1s (FEV1)) * ACT: Asthma Control Test i * ACQ: Asthma Control Questionnaire * MiniAQLQ: Mini Asthma Quality of Life Questionnaire * SGRQ: Saint Georges Respiratory Questionnaire * SF36: 36-item Short-Form Health Survey * EQ 5D 5L: 5Level-EuroQualityoflife Instrument 5 Dimension * EQ 5D VAS: EuroQol Visual Analogue Scale

    Time frame: 1 month

Secondary outcomes

  1. Usability testing

    Questionnaire feasibility: Average filling percentage, mean filling time, need for help in responding, identification of problematic items, reason why they are problematic

    Time frame: 6 months

  2. Test-retest reliability

    Test-retest reliability (stability of scores over time when no change is expected in the concept of interest): intraclass correlation coefficient of SAQ M1 vs M6 within stable ACT score group adjusted on oral corticosteroids dose.

    Time frame: 6 months

  3. Ability to detect change

    Ability to detect change (evidence that a Patient Reported Outcome instrument can identify differences in scores over time in individuals or groups who have changed with respect to the measurement concept): Wilcoxon signed rank-test on oral corticosteroid dose, comparing individuals at M1 and M6 for whom an asthma biotherapy has been initiated in that time interval.

    Time frame: 6 months

  4. Minimal Clinically Important Difference (MCID)

    MCID (minimal difference of significance among any differences observed): anchored base estimation using a global 15point scale ranging scale to measure change.

    Time frame: 6 months

07

Study locations

1 site
  • Bichat-Claude Bernard University Hospital
    Paris, 75018, France
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04520633
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Aug 20, 2020
Start date
Nov 17, 2020
Primary completion
Jul 6, 2023
Completion
Jul 6, 2023
Last update
Dec 15, 2023

Study contacts

Camille Taillé, MD-PHD
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion